loading page

Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score.
  • +7
  • Luis Perez de Llano,
  • Ignacio Davila,
  • Eva Martinez-Moragon,
  • Javier Domínguez-Ortega,
  • Carlos Almonacid,
  • Carlos Colás,
  • Juan Luis García-Rivero,
  • Loreto Carmona,
  • María Jesús García de Yébenes,
  • Borja G Cosio
Luis Perez de Llano
Hospital Universitario Lucus Augusti

Corresponding Author:eremos26@hotmail.com

Author Profile
Ignacio Davila
University Hospital, University of Salamanca
Author Profile
Eva Martinez-Moragon
University Hospital Dr Peset, Valencia
Author Profile
Javier Domínguez-Ortega
Hospital La Paz Institute for Health Research (IdiPAZ)
Author Profile
Carlos Almonacid
Hospital Universitario Ramón y Cajal Servicio de Neumología
Author Profile
Carlos Colás
Instituto de Investigacion Sanitaria de Aragon-Hospital Clinico
Author Profile
Juan Luis García-Rivero
Hospital Comarcal de Laredo
Author Profile
Loreto Carmona
Instituto de Salud Musculoesquelética
Author Profile
María Jesús García de Yébenes
Instituto de Salud Musculoesquelética.
Author Profile
Borja G Cosio
Hospital Son Espases, Palma de Mallorca; CIBER Enfermedades Respiratorias (CIBERES), Spain.
Author Profile


Background: There is a lack of tools to holistically quantify the response to monoclonal antibodies (mAbs) in severe uncontrolled asthma (SUA) patients. The aim of this study was to develop a valid score to assist specialists in this clinical context. Methods: The score was developed in 4 subsequent phases: (1) elaboration of the theoretical model of the construct intended to be measured (response to mAbs); (2) definition and selection of items and measurement instruments by Delphi survey; (3) weight assignment of the selected items by multicriteria decision analysis (MCDA) using the Potentially All Pairwise RanKings of all possible Alternatives (PAPRIKA) methodology via the 1000Minds software; and (4) face validity assessment of the obtained score. Results: Four core items, with different levels of response for each of them, were selected: “severe exacerbations”, “oral corticosteroid use”, “symptoms” (evaluated by Asthma Control Test: ACT) and “bronchial obstruction” (assessed by FEV1 % theoretical). “Severe exacerbations” and “oral corticosteroid maintenance dose” were weighted most heavily (38% each), followed by “symptoms” (13%) and “FEV1” (11%). Higher scores in the weighted system indicate better response and the range of responses runs from 0 (worsening) to 100 (best possible response). Face validity was high (intraclass correlation coefficient: 0.86). Conclusions: The FEOS score (FEV1, Exacerbations, Oral corticosteroids, Symptoms) allows clinicians to quantify response in SUA patients who are being treated with mAbs.